Profile of lebrikizumab and its potential in the treatment of asthma

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Interleukin (IL)-13 has been associated with multiple inflammatory features of asthma. It affects multiple cellular lines in asthma and is a key mediator in airway hyperreactivity and remodeling. Periostin, an extracellular protein, has been used as a surrogate marker of IL-13 activity and has been linked to airway remodeling by inducing subepithelial fibrosis. Lebrikizumab is a humanized monoclonal antibody that targets IL-13. Studies have demonstrated promising results with lebrikizumab therapy in asthma with regard to pulmonary function and exacerbation rates, especially on those patients with surrogate markers of T helper cell type 2-driven inflammation (ie, elevated immunoglobulin E levels, eosinophil counts, periostin levels). Lebrikizumab appears to be a safe therapy, but there are ongoing studies evaluating its efficacy and safety profile. Other therapies that target IL-13 and the receptor of IL-4/IL-13 have been studied, but future studies are needed to determine their role in the treatment of asthma.

Original languageEnglish (US)
Pages (from-to)87-92
Number of pages6
JournalJournal of Asthma and Allergy
StatePublished - Aug 10 2015


  • Asthma
  • IL-13
  • Lebrikizumab
  • Periostin
  • Severe asthma

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy


Dive into the research topics of 'Profile of lebrikizumab and its potential in the treatment of asthma'. Together they form a unique fingerprint.

Cite this